New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Research \ Clinical Trials \ Updates
HD Study for Those At Risk

Posted to the HDL: 01 Aug 2007


Jessica Young, BS

Social and Behavioral Research Branch National Human Genome Research Institute National Institutes of Health
31 Center Drive (31/B1B36)
Bethesda, MD 20892
Phone: (301) 443-0743
youngjes@mail.nih.gov
You are invited to participate in a study conducted by researchers at the Johns Hopkins University and the National Human Genome Research Institute. The purpose of our study is to learn more about how people who are at risk for Huntington’s disease are talking about Huntington’s disease to family and close friends and to learn how people are adapting to their risk for Huntington’s disease. By understanding more about this process, we hope that healthcare providers will be able to better serve their patients who are at risk for Huntington’s disease.

The study involves filling out one survey that takes about 30-40 minutes to complete. If you take part in the study, you will be reimbursed with a $5 gift card to Wal-Mart for your time. The survey asks about your communication about Huntington’s disease to family and close friends and also asks about your general thoughts and feelings about yourself and your life.

In order to take part in the study, you must fulfill the following eligibility criteria:

  1. You are 18 years or older.
  2. You can read and write English.
  3. You had a positive predictive genetic test result for Huntington’s disease OR you have a family history of Huntington’s disease and have not had predictive testing.
  4. You currently have no symptoms of Huntington’s disease.
  5. If you have had predictive genetic testing for Huntington’s disease, you received your results greater than six months ago.

There are two ways to take the survey:

  1. Take the survey online at: http://www.surveymonkey.com/s.aspx?sm=3VKcPF_2fB2EabRWv_2fBXfpwg_3d_3d
    The password to open the survey is “georgehuntington”.

    OR
  2. Fill out the paper copy. If you would prefer to fill out a paper version, please contact Jessica Young at (301) 443-0743 to have a copy of the survey and a stamped return envelope mailed to you. Then send it back to us in a self-addressed stamped envelope, at no cost to you. The survey is anonymous so please do not sign it or include your return address.

    If you decide to fill out the paper copy, you will find two versions of the survey. You only need to complete only the survey version that applies to you. Survey A is for people who have had genetic testing for Huntington’s disease. Survey B is for people who have not had genetic testing for Huntington’s disease, but are at risk for Huntington’s disease based on a family history of Huntington’s disease. Please complete only the survey version that applies to you.

    If you are willing to take part in this study, please read the consent form (within the survey) and check the box that acknowledges that you have read and agreed to the terms presented in the consent document.

    In addition, if you are willing, please feel free to pass on the online survey link and the password to others who might be eligible (see criteria above) and willing to fill out the survey. If the person would prefer to fill out a paper version of the survey, please ask them to contact the researchers (contact information below).

    If you have any problems or questions about this study, or about your rights as a participant, please contact the researchers (contact information below). Thank you for your time and for being willing to fill out this survey. We look forward to learning from your answers.

    Sincerely, Jessica Young, BS Barbara Biesecker, MS, CGC
    Co-investigator Co-investigator, JHU/NHGRI
    Genetic Counseling Graduate Student Genetic Counseling Training Program
    JHU/NHGRI Genetic Counseling Program (301) 496-3979
    (301) 443-0743 barbarab@mail.nih.gov
    Toll-free: (866) 585-7192 (press 4)
    youngjes@mail.nih.gov

    # # #

    Source:

    print this
    printer friendly
    version

     

    Read the HDAC/HDLighthouse Forum. Post your comments
       
Related Topics
Research focusing on the formation of aggregates caused by HD
 
Research related to the role Brain Derived Neurotrophic Factor has on the pathology of HD in the brain
 
Research related HD and it's general affect on the brain
 
Research related to drugs and supplements that may delay onset and slow progression of Huntington's Disease.
 
Research focusing on gene therapy.
 
Research focusing on gene transcription.
 
General research related to HD
 
Research studying the genetics of Huntington's Disease
 
Research studying the Immune System and it's effect on the progression of HD
 
Research studying the brain tissue and research related to stem cells
 
Recent Updates
24 May 2010
Neurosearch Amends the ACR-16 Results
Statistical significance not achieved on primary endpoint.
 
3 Feb 2010
The European trial of ACR16 yields good results
ACR16 improves voluntary and involuntary movement. This is wonderful news!
 
31 Jan 2010
A Sirtuin Inhibitor Enters Phase1a Clinical Trials in Europe
Siena Biotech announces a safety and tolerability study with healthy volunteers, preparatory to trials in HD patients.
 
3 Jun 2009
Medivation to begin a Phase III trial of Dimebon
Medivation is sponsoring a randomized, double-Blind, placebo-controlled, Phase III trial of Dimebon in patients with mild to moderate Huntington’s Disease
 
23 Apr 2009
Minocycline Phase II clinical trial results are disappointing
 
18 Jul 2008
Participants needed for qualitative studies of JHD
The University of Iowa is recruiting participants for two important new studies.
 
9 Jun 2008
The Research Pipeline - taking drugs from the lab to the clinic
Here's an overview of some of the more promising potential treatments moving through the research pipeline.
 
12 Mar 2008
Phase III creatine trial
NCCAM and the Orphan Product Division of the FDA is funding a phase III clinical trial of medicinal grade creatine.
 
1 Oct 2007
ACR16 closer to Phase III clinical trials
Neurosearch applies for permission to start Phase III clinical trials of ACR16, a dopamine stabilizer, in Europe and the U.S.
 
30 Sep 2007
Research Study for those At Risk
Last call for participants in an At Risk study.
 

All Updates for Clinical Trials
Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org